Nexturastat B
| Code | Size | Price |
|---|
| AG-CR1-3902-M001 | 1 mg | £60.00 |
Quantity:
| AG-CR1-3902-M005 | 5 mg | £160.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C (short term), -20°C (long term).
Documents
Further Information
Alternate Names/Synonyms:
4-((1-Butyl-3-(1H-indazol-6-yl)ureido)methyl)-N-hydroxybenzamide
Appearance:
Off white solid.
CAS:
1648893-33-7
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.Protect from light.
InChi:
InChI=1S/C20H23N5O3/c1-2-3-10-25(13-14-4-6-15(7-5-14)19(26)24-28)20(27)22-17-9-8-16-12-21-23-18(16)11-17/h4-9,11-12,28H,2-3,10,13H2,1H3,(H,21,23)(H,22,27)(H,24,26)
InChiKey:
SDIVUCIYBAWAQP-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1648893-33-7. Formula: C20H23N5O3. MW: 381.4. Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50=3nM). Displays high selectivity over HDAC1 (300-fold). More soluble analog of nexturastat A (Prod. No. AG-CR1-3901). Suppresses cell proliferation of B16 cells (GI50=14.3µM) and human lymphoma cells HuT-78 at a slightly lower concentration than nexturastat A. Shown to be effective in a mouse melanoma tumor xenograft model, increasing tumor volumes in vivo. Down-regulates the production of IL-10. HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
Molecular Formula:
C20H23N5O3
Molecular Weight:
381.4
Package Type:
Vial
Product Description:
Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50=3nM). Displays high selectivity over HDAC1 (300-fold). More soluble analog of nexturastat A (Prod. No. AG-CR1-3901). Suppresses cell proliferation of B16 cells (GI50=14.3µM) and human lymphoma cells HuT-78 at a slightly lower concentration than nexturastat A. Shown to be effective in a mouse melanoma tumor xenograft model, increasing tumor volumes in vivo. Down-regulates the production of IL-10. HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
Purity:
>98% (HPLC)
SMILES:
CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC1=CC2=C(C=NN2)C=C1
Solubility Chemicals:
Soluble in DMSO, methanol or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation: K.V. Woan, et al.; Mol. Oncol. 9, 1447 (2015) | Exploration of some new HDAC inhibitors for cancer and CNS diseases: A.P. Kozikowski; 13th Annual Discovery on Target (presentation) (2015)
Related Products
| Product Name | Product Code | Supplier | Nexturastat A | AG-CR1-3901 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACY-775 | AG-CR1-3903 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DMAPB | AG-CR1-3904 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PMPH | AG-CR1-3905 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DABPH | AG-CR1-3906 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MBIMPH | AG-CR1-3907 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MBIMPH F-Analog 1 . HCl | AG-CR1-3908 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MBIMPH F-Analog 2 | AG-CR1-3909 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||